The R336Q mutation in human mitochondrial EFTu prevents the formation of an active mt-EFTu·GTP·aa-tRNA ternary complex  by Valente, Lucia et al.
Biochimica et Biophysica Acta 1792 (2009) 791–795
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isThe R336Q mutation in human mitochondrial EFTu prevents the formation of an
active mt-EFTu·GTP·aa-tRNA ternary complex
Lucia Valente a,1, Narumi Shigi b, Tsutomu Suzuki b, Massimo Zeviani a,⁎
a Unit of Molecular Neurogenetics, IRCCS Foundation, Neurological Institute C. Besta, Via Temolo 4 - 20126 Milano, Italy
b Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, Bldg. 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan⁎ Corresponding author. Tel.: +39 223942630; fax: +
E-mail address: zeviani@istituto-besta.it (M. Zeviani
URL: http://www.mitopedia.org (M. Zeviani).
1 Present address: Institute of Medical Technology an
Biokatu 6, 33014, Tampere, Finland.
0925-4439/$ – see front matter © 2009 Elsevier B.V. A
doi:10.1016/j.bbadis.2009.06.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 March 2009
Received in revised form 6 May 2009
Accepted 8 June 2009
Available online 12 June 2009
Keywords:
Mitochondrial translation
mt-EFTu mutation
mt-EFTu binding activityThe mitochondrial translational machinery allows the genes encoded by mitochondrial DNA (mtDNA) to be
translated in situ. Mitochondrial translation requires a number of nucleus-encoded protein factors, some of
which have been found to carry mutations in patients affected by mitochondrial encephalomyopathies. We
have previously described the ﬁrst, and so far only, mutation in the mitochondrial elongation factor Tu, mt-
EFTu, in a baby girl with polycystic encephalopathy, micropolygyria, and leukodystrophic changes. Despite
that the mutant mt-EFTu was present in normal amount in the patient's tissues, mitochondrial translation
was severely reduced, determining multiple defects in the amount and activity of mtDNA-dependent
respiratory chain complexes. By an in-vitro reconstructed translational system, we here provide evidence
that the mutant mt-EFTu variant fails to bind to aminoacylated mitochondrial tRNAs, thus explaining the
observed impairment of mitochondrial translation. This is the ﬁrst analysis on the molecular mechanism of a
mtDNA translation defect due to a nuclear gene mutation.© 2009 Elsevier B.V. All rights reserved.1. IntroductionMammalian cells have two distinct translation systems, cytosolic
and mitochondrial, the latter being closer to that of prokaryotes, in
agreement with the ancestral origin of mitochondria. The mitochon-
drial system allows the in situ translation of genes encoded by
mitochondrial DNA (mtDNA). In addition to tRNAs and rRNAs encoded
by, and transcribed from, mtDNA itself, the mitochondrial transla-
tional machinery requires a number of nucleus-encoded protein
factors, which are translated in the cytosol and imported into
mitochondria [1].
The translation process is organized in 3 phases: (i) initiation, where
messenger RNA binds to the ribosome; (ii) elongation, where the
nascent peptide is actually synthesized; and (iii) termination,where the
process ends and the ribosome can be released from the mRNA.
The elongation phase requires the concerted action of (at least)
three mitochondrion-speciﬁc factors: (i) mitochondrial elongation
factor 1 (mt-EFG1), which allows the nascent peptidyl-tRNA to move
from the A to P sites of the ribosome; (ii) mitochondrial elongation
factor Tu (mt-EFTu), which forms a ternary complex with GTP and
aminoacylated (aa)-tRNA and promotes the codon-directed binding of
the aa-tRNA to the A-site of the ribosome.; and (iii) mitochondrial39 223942619.
).
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ll rights reserved.elongation factor Ts (mt-EFTs), which promote the exchange of
guanine nucleotide on mt-EFTu, thus promoting the catalytic use of
this factor.
Human mt-EFTu [2] is encoded by a 9-exon gene located on
chromosome 16p11.2 (an intronless pseudogene is on 17q11.2 [3]).
The crystallographic structure of bovine mt-EFTu-GDP [4] shows
the presence of three domains, I— a Mg++-GTPase domain, II— an
aa-tRNA binding domain, and III— a mt-EFTs binding domain. The
structure of mt-EFTu is similar to that of Escherichia coli and Thermus
aquaticus, but the mitochondrial protein contains an 11-aa C-terminal
extension that is hypothesized to increase its afﬁnity to the mt-tRNA
species, which are shorter than cytosolic tRNAs [4,5]. In a dynamic re-
construction of themt-EFTumechanism, domains II and III are relatively
ﬁxed, whereas domain I rotates in the mt-EFTu-GDP vs. mt-EFTu-GTP
states [6,7]. Mt-EFTu is recycled by mt-EFTs, which replaces GDP with
GTP.Mt-EFTu-GDPbinds tomt-EFTs, thus altering theMg2+binding site
and reducing the afﬁnity of mt-EFTu for guanine nucleotides [8]. Mt-
EFTs is then released and a new GTP molecule is bound to mt-EFTu.
In the last years the number of mitochondrial translation defects
found in human patients that are due to mutations in nucleus-encoded
factors has expanded, including mutations in mt-EFG1 [9,10,11],
MPRS16 [12], mt-EFTs [13], MPRS22 [14] and different mitochondrial
aminoacyl-tRNA synthetase (for a complete review see ref. [15]).
We previously described the ﬁrst, and so far only, mutation in mt-
EFTu [11], in a baby patient with polycystic encephalopathy, micro-
polygyria, and leukodystrophic changes. We provide here mechanistic
evidence, which explains impaired mitochondrial translation by the
mt-EFTu mutant variant.
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2.1. Expression and puriﬁcation of human mt-EFTu in E. coli
2.1.1. Cloning in a procaryotic expression vector
According to the protein sequence deduced by the NCBI annotation
NM_003321, the mutation in our patient determines a change of the
arginine at position 339 into a glutamine. However, the human
mt-EFTu protein sequence deduced from NM_003321 contains two
methionine residues in the N-terminus, one at position +1, the other
at position +4. In all other mammalian species the ﬁrst methionine
residue (M1) is missing, and the protein starts at the positionFig. 1. Structures and sequences of human mt-EFTu and bovine mt-tRNASer species used in
targeting sequence is in italic. An arrow indicates the R336 residue. Modiﬁed forward (FW
nucleotide sequence. The sequence corresponding to the restriction sites are underlined. (Pcorresponding to human M4. It is very likely that in fact the true
human mt-EFTu protein is three-residue shorter than the sequence
predicted by NM_003321. This redeﬁnition of the primary structure of
human mt-EFTu is indeed found in the Expasy-Swissprot database
(accession no. P49411). Accordingly, we will redeﬁne the protein
sequence of human mt-EFTu as corresponding to the P49411
annotation, and as a consequence the R339Q will be replaced by
R336Q. The cDNA encoding the putative human mt-EFTuwt mature
form, tagged with a hexahistidine (His) stretch at the C terminus, was
cloned into the procaryote expression vector pET24(a) (Novagen). The
cDNA corresponding to NCBI NM_003321 was ﬁrst PCR-ampliﬁed by
high-ﬁdelity Taq Gold (Invitrogen) with modiﬁed primers containingthis study. (Panel a) Human mt-EFTu aminoacid sequence. The putative mitochondrial
-NdeI) and reverse (Rev-XhoI) primers used for cDNA cloning are aligned along the
anel b) Bovine mitochondrial tRNASer primary and secondary structures.
Table 1
In-vitro translation assay.
EFTu polyU [14C]Phe(pmol)±SD
1 μM EFTu WT + 4.027±0.350
− 0.740±0.067
1 μM EFTu R336Q + 0.725±0.014
− 0.852±0.014
MIX: 0.5 μM EFTu WT+0.5 μM EFTu R336Q + 3.229
− 0.787
Data represent the amount of TCA-precipitable [14C]Phe expressed in pmol±standard
deviation, produced in 30′ in the presence (+) or absence (−) of poly(U) RNA, and of
mt-EFTuwt (WT) or mt-EFTuR336Q (R336Q) recombinant proteins or both WT and
R336Q in ratio 1:1.
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(reverse primer, Rev), as follows:
Fw (NdeI) 5′-GGTGCCGCCATATGGCCGTGGAGGCCAAGAAG-3′
Rev (XhoI) 5′-GCACTCGAGACCCCATTTGATATTCTTC-3′.
PCR conditions were: hot start 95 °C 10′, 25 cycles of denaturation
95 °C 45″, annealing 56 °C 1′, elongation 72 °C 2′30″, and a last extension
cycle 72 °C 5′. The cDNA fragment encodes a proteinmissing the ﬁrst 43
N-terminal aminoacids of the protein sequence P49411. We also
modiﬁed the forward primer in order to introduce an initiation
methionine at position +1 of the recombinant protein (Fig. 1a). Both
the PCR insert and the pET24(a) were digested with NdeI and XhoI
restriction enzymes, ligated using T4 DNA ligase (Invitrogen) for 1 h at
26 °C, and used to transform competent cells. The insert was veriﬁed by
sequence analysis. The cDNA encoding mature EFTuR336Q was obtained
by directed mutagenesis (Stratagene) using the protocol recommended
by the manufacturer and the following modiﬁed primers:
Fw 5′-GGGAGGACTTGCGGCAGGGCCTGGTCATGGT-3′
Rev 5′-ACCATGACCAGGCCCTGCCGCAAGTCCTCCC-3′.
2.1.2. Expression of recombinant mt-EFTu in E. coli
After transformation with the suitable recombinant plasmids,
Rosetta(DE3)pLysS E. coli competent cells (Novagen) were grown to
mid-log phase in 2 l of LBmediawith 25 μg/ml kanamycin and 34 μg/ml
chloramphenicol at 37 °C under constant agitation, and recombinant
protein expression was induced with 0.4 mM IPTG at 25 °C for 4 h.
2.1.3. mt-EFTu puriﬁcation
Cells expressing recombinant, His-tagged, mature mt-EFTuwt and
mt-EFTuR336Qwere collected by centrifugation at 5860 ×g for 15′ at 4 °C,
resuspended in lysis buffer (50mMTris–HCl pH 7.5,100mMKCl,10mM
MgCl2), centrifuged again at 5860 ×g for 15′ at 4 °C, and pellets were
fast-frozen in liquid nitrogen. The frozen cells were kept on ice,
resuspended with 50 mM Tris–HCl pH 7.6, 100 mM KCl, 10 mM MgCl2,
10% glycerol, 7 mM 2-β-mercaptoethanol, 0.2 mM phenylmethanesul-
fonyl ﬂuoride PMSF, 0.1% Triton X-100, and sonicated with a Brandson
450D sonicator on ice. Samples were ultracentrifuged at 100,000 ×g for
1 h at 4 °C in a Beckman ultracentrifuge in a ﬁxed rotor. The proteins
were then puriﬁed by chromatography through a His-TrapTM HP
column (GE Healthcare) by using a FPLC Amersham bioscience AKTA
primer puriﬁer, injected with 50 mM Tris–HCl pH 7.6, 100 mM KCl,
10mMMgCl2,10% glycerol, 7mM2-β-mercaptoethanol,10 μMGDPand
elutedwith500mMimidazole (5% to 100%). The fractions enrichedwith
recombinant EFTuHis proteins were collected, dialyzed with a Slide-A-
Lyzer dialysis cassette (cutoff at 10,000 Da), in 20 mM Tris–HCl pH 7.6,
40 mM KCl, 1 mM MgCl2, 10% glycerol, 6 mM 2-β-mercaptoethanol at
4 °C. The puriﬁed proteins were stored at−80 °C until use.Fig. 2. In-vitro translation assay. The histograms display the amount of TCA-precipitable
[14C]Phe expressed in pmol, produced in 30′ in the presence (+) or absence (−) of
translable poly(U) RNA, and of mt-EFTuwt (WT) or mt-EFTuR336Q (R336Q) recombinant
proteins. The bars represent±standard deviation. Black bars refer to experiments with
WT, while the grey bars refer to experiments with R336Qmt-EFTu species. Student's t-test
analysis: ⁎⁎pb0.01.2.1.4. Circular dicroism
The far-UV (200–260 nm) CD spectra of the proteinweremeasured
by a J-720 automatic spectropolarimeter (Japan Spectroscopic Co.) at
10 °C. The buffer was 0.4 mM Tris–HCl 7.4, 40 mM KCl, 1 mM MgCl2,
0.2% Glycerol and 0.001% 2-β-mercaptoethanol. The protein concen-
trations were 0.049 mg/ml of wild-type and 0.027 mg/ml of mutant.
The percentages of mt-EFTu fraction were estimated by SDS-PAGE.
2.2. mt-tRNA aminoacylation
Native tRNA for mitochondrial Serine, UGA and GCU, were puriﬁed
from bovine liver as previously described [16]. Recombinant Ser-mt-
tRNA Synthetase was a kind gift of Prof. Kimitsuna Watanabe.
Aminoacylation was performed using the method described by
Pingoud et al. [17]. Brieﬂy tRNAs were incubated in 100 μl with
100mMHepes pH 7.5,10mMKCl, 5mMMgCl2,1mMSpermine, 2mM
ATP, 1 mM DTT, 10 μCi [3H]Serine, 18 μg Ser-mt-tRNA-Synthetase and
≈0.5 μg mt-tRNASer(GCU) or mt-tRNASer(UGA), at 37 °C for 30′.
Aminoacylated Ser-tRNASer species were puriﬁed with a NAPTM
column (GE Healthcare), precipitated with ethanol, resuspended in
10 mM KOAc pH 5.2 and stored at−80 °C until use. In spite that both
the nucleotide sequence and the predicted secondary structure of
human mt-tRNASer(GCU) and mt-tRNASer(UGA) differ greatly from each
other (Fig. 1b), they both fold into a similar tertiary structure [18] and
share the same mt-seryl-tRNA synthetase [19].
2.3. In-vitro translation assay
Poly(U)-directed poly-phenylalanine synthesis with Phe-mt-tRNA
(Phe) was carried out in an in-vitro translation system consisting of
puriﬁed E. coli ribosomes (70 S), prepared as described [20], EFG from
E. coli [21], poly(U) and energy regeneration system, essentially as
described [22,23],with slightmodiﬁcations. Brieﬂy,wemixed in a total
volume of 10 μl a ﬁnal concentration of 50mM Tris–HCl pH 8.0, 10 mM
MgCl2, 10 mM NH4Cl, 1 mM DTT, 0.5 mM GTP, 2 mM ATP, 2.5 U/ml
Pyruvate kinase, 2.375 mM Phosphoenolpyruvate, 0.5 mg/ml poly(U)
RNA, 2 μM E. coli EFG, 1 μM recombinant EFTu, 6 μg/ml recombinant
human mt-tRNAPhe synthetase, 75 pmol/ml puriﬁed bovine mt-
tRNAPhe, 0.01 mM [14C]Phe and 50 pmol/ml puriﬁed E. coli ribosomes.
The reaction was allowed to proceed for 30′ at 37 °C. Blank reactions
were carried out in parallel for each sample by omitting poly(U) in the
reaction mix. Aliquots of 8 μl per sample were spotted onto
nitrocellulose ﬁlters, treated with 10% trichloroacetic acid (TCA) for
60′ at 85 °C followed by cold 10% TCA for 30′. After washing in 100%
ethanol, the amount of poly-[14C]Phe peptides was measured in a
liquid scintillation counter. The conversion of cpm into pmol of [14C]
Phe was obtained by constructing a linear standard plot (not shown).
Values were expressed as pmol of precipitable [14C]Phe.
2.4. Non-enzymatic hydrolysis protection assay
The ability of wild-type and mutant mt-EFTu (mt-EFTuwt,
mt-EFTuR336Q) to protect Ser-tRNASer from spontaneous deacylation
Fig. 3. Circular dicroism spectra of the puriﬁed EFTu proteins: mt-EFTuwt is represented
by a black line, mt-EFTuR336Q by a red line.
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10 pmol of puriﬁed EFTuwt or EFTuR336Q were incubated with 8 pmol of
bovine aminoacylated Ser-mt-tRNA(UGA) or Ser-mt-tRNA(GCU), in 75mM
Tris–HCl pH7.6, 75mMNH4Cl,15mMMgCl2, 7.5mMDTT, 60 μg/ml BSA,
1 mM GTP, 2.4 mM phosphoenol-pyruvate/0.1 mU pyruvate kinase
(PEP/PK), in a ﬁnal volume of 40 μl. Incubation was carried out at 30°C
for 90 min and aliquots (8 μl) were withdrawn at various times (t=0′,
30′, 60′, and 90′) and precipitated in 5% cold TCA. The precipitate was
collected on nitrocellulose ﬁlters and the amount of EFTu-GTP-[3H]Ser-
tRNASer was quantiﬁed using a liquid scintillation counter. The
conversion of cpm into pmol of [3H]Ser-tRNASer was obtained by
constructing a linear standard plot (not shown). The amount of EFTu-
GTP-[3H]Ser-tRNASer was expressed as ln(xt/x0) versus time, where xt is
the concentration of EFTu-GTP-[3H]Ser-tRNASer at time=t and x0 is the
concentration of EFTu-GTP-[3H]Ser-tRNASer at time=0.
2.5. Statistical analysis
Unpaired, two-tail Student's t-test was used for statistical analysis.
3. Results and discussion
In T. aquaticus, EFTu binds the 5′-side of the aa-tRNA acceptor stem
inside a pocket formed by the three domains (I, II, III). Therefore, many
residues can be involved in this important step [25]. Previous studies
on both E. coli and bovine mt-EFTu species suggest that the wild-type
R338 residue is involved in aminoacyl-tRNA binding [24], whereas theFig. 4. Non-enzymatic hydrolysis protection assay of Ser-mt-EFTu-tRNASer. Time course of ln(xt/
(left panel) and [3H]Ser-tRNASer(GCU) (right panel) as a function of time (seeMaterials andmeth
Closed red squares and continuous line represent values obtained with mutant mt-EFTuR336Q.
mt-EFTu from the reaction mix. Student's t-test analysis of the mt-EFTuR336Q form vs. mt-EFTucontiguous L341 residue is important for the stability of the mt-EFTu–
GTP–mt-EFTs complex [26].
In order to test the functional consequences of the R336Qmutation,
we expressed in, and puriﬁed from, E. coli, the allegedly mature forms
ofmt-EFTuwt andmutantmt-EFTuR336Q, obtained byexpressing cDNAs
lacking the 43 N-terminal aminoacid residues of the P49411 reference
sequence for human mt-EFTu, which are predicted to encompass the
mitochondrial targeting signal (Fig. 1a).
First, we tested both mt-EFTuWT and mt-EFTuR336Q variants in an
in-vitro translation system, which can translate a poly(U) RNA stretch
into [14C] radiolabeled Phe oligopeptides. Robust in-vitro synthesis of
poly-[14C]Phe was measured with mt-EFTuwt, whereas the values
obtained with mt-EFTuR336Q were virtually identical to those of the
blank reactions, indicating severe loss of function (Fig. 2 and Table 1).
As shown in Table 1, in-vitro translation was also normal in the
presence of a 1:1 mixture of mt-EFTuwt andmt-EFTuR336Q, in line with
the genetic features of the disease that was inherited as a strictly
recessive trait.
These results, obtained in vitro, are in agreement with the
profound translation defect detected in vivo on ﬁbroblasts from our
mt-EFTuR336Q mutant patient [11]. However, both these results could
not deﬁne the mechanistic defect associated with mt-EFTuR336Q,
which could be due to either a conformational alteration of the protein
or to functional impairment, for instance in the binding of GTP,
aminoacylated-mt-tRNA, or both, to form an active mt-EFTu–GTP–
aminoacyl-tRNA complex.
To gain insight into the mechanistic abnormality underlying the
translational defect, we ﬁrst used circular dicroism analysis on puriﬁed
proteins, in order to test whether the mutant and wild-type species
were structurally different. As shown in Fig. 3, the spectra obtained from
the two protein species were perfectly overlapping, indicating that no
conformational changes were present in mt-EFTuR336Q vs. mt-EFTuwt.
This result, which is concordant with previous in-silico structural
predictions [11] and with the demonstration that mutant mt-EFTuR336Q
is present in normal amount inﬁbroblasts and tissues of our patient [11],
prompted us to testwhether themutation could impair the formation of
the mt-EFTu–GTP–aminoacyl-tRNA complex, as suggested by previous
studies in procaryotes [24,26]. We then investigated the kinetics of mt-
EFTuR336Q vs. mt-EFTuwt binding activity by using an in-vitro non-
enzymatic hydrolysis protection assay. This experiment is based on the
ability of mt-EFTu to bind aminoacylatedmt-tRNAs, in our case in vitro-
aminoacylated Ser-mt-tRNASer(UCG) and Ser-mt-tRNASer(UGA), thus
protecting them from spontaneous degradation, which is well demon-
strated to occur by the “blank” experiments displayed in Fig. 2. As shown
in Fig. 4, mutant mt-EFTuR336Q failed to protect both Ser-mt-tRNASerx0) values (symbols) and linear regression (lines) of TCA-precipitable [3H]Ser-tRNASer(UGA)
ods). Closed black squares and continuous line represent values obtainedwithmt-EFTuwt.
Open circles and dotted line represent blank reactions obtained by omitting recombinant
wt: ⁎⁎⁎pb0.001.
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functionally active ternary complex.
In conclusion, the profound defect of translation associated with
the R336Q change in mt-EFTu is not caused by structural abnor-
malities of the protein, but is rather determined by functional
impairment in the interaction with aminoacylated-tRNA, thus
preventing translation to proceed. The R336Q mutation is located on
a solvent-exposed β-sheet on the outer surface of domain II of
mammalian mt-EFTu [11]. This position makes it unlikely that the
R336Q mutation can determine a drastic structural rearrangement of
the protein, because the interaction with neighbor amino acid
residues is minimal. Since domain II constitutes the tRNA-binding
site of mt-EFTu [5], we have previously hypothesized that the most
probable effect of the R336Q substitution is to hamper the formation
of the GTP:EFTu:aminoacyl-tRNA ternary complex. This hypothesis,
which was supported by the demonstration that the amount and
electrophoretic mobility of mt-EFTuR336Q are both normal [11], is now
proven mechanistically by the results of our protection assay.
The virtually complete suppression of mt-EFTuR336Q binding
capacity also explains the extreme severity of the recessive syndrome
determined by the mutation in humans, although it is surprising that
the pathological and clinical features of the disease were restricted to
the central nervous system, in spite that the severe mitochondrial
translation defect was generalized, and mt-EFTu is an essential
constitutive protein expressed in all cells and tissues. Tissue-
speciﬁcity is an unsolved problem in many mitochondrial disorders,
which suggests the presence of complex, still unknown regulatory and
control networks. Future work is warranted to clarify this important
aspect of mt-EFTu as well as other proteins involved in mitochondrial
biogenesis.
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